SPANX-B Polypeptides for Multi-Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy lacks effective antigens for treating various types of cancer beyond prostate cancer, with a need to identify additional tumor-associated antigens to evoke immune responses.
Innovation Solution
The use of SPANX-B polypeptides, specifically immunogenic peptides of nine to twelve amino acids, to generate cytotoxic T cells and activated helper T cells that recognize and target tumor cells, particularly in melanoma, lung, colon, renal, ovarian, and breast carcinomas, by eliciting an immune response and activating T cells in vivo or in vitro.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prostate cancer-associated antigens are used for immunotherapy, then immune response against prostate cancer is improved, but applicability to other cancer types is limited
Solution Approach 1:
The patent identifies SPANX-B as a universal tumor-associated antigen that is widely expressed across multiple cancer types including melanoma, lung, colon, renal, ovarian, and breast carcinomas. By targeting SPANX-B instead of prostate-specific antigens, the immunotherapy approach achieves multi-functionality and broad applicability across different malignancies while maintaining effective immune response generation.
2Reliability
If tumor-associated antigens are identified for immunotherapy, then specific immune response is improved, but availability of effective antigens for various cancers is insufficient
Solution Approach 1:
The patent performs preliminary identification and characterization of SPANX-B as a tumor-associated antigen before developing immunotherapy strategies. By mapping HLA-restricted epitopes and demonstrating T cell recognition in advance, the patent prepares a ready-to-use antigen target that can be immediately applied across multiple cancer types, eliminating the need for separate antigen discovery processes for each malignancy.
Data Source
AI summary
It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.